{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:47:02Z","timestamp":1787993222789,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40801-022-00316-4","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T09:03:33Z","timestamp":1656579813000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment Patterns During Major Depressive Episodes Among Patients with Major Depressive Disorder: A Retrospective Database Analysis"],"prefix":"10.1007","volume":"9","author":[{"given":"Rakesh","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Higa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Keyloun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machaon","family":"Bonafede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"issue":"4","key":"316_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","volume":"75","author":"DS Hasin","year":"2018","unstructured":"Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiat. 2018;75(4):336\u201346.","journal-title":"JAMA Psychiat"},{"issue":"15","key":"316_CR2","first-page":"1517","volume":"317","author":"MJ Friedrich","year":"2017","unstructured":"Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317(15):1517.","journal-title":"JAMA"},{"issue":"6","key":"316_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","volume":"39","author":"PE Greenberg","year":"2021","unstructured":"Greenberg PE, Fournier AA, Sisitsky T, Simes M, Berman R, Koenigsberg SH, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2021;39(6):653\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"316_CR4","doi-asserted-by":"publisher","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","volume":"15","author":"C Otte","year":"2016","unstructured":"Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;15(2):16065.","journal-title":"Nat Rev Dis Primers"},{"issue":"172","key":"316_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jad.2014.10.010","volume":"1","author":"EI Fried","year":"2015","unstructured":"Fried EI, Nesse RM. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. J Affect Disord. 2015;1(172):96\u2013102.","journal-title":"J Affect Disord"},{"key":"316_CR6","unstructured":"American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder. 3rd ed. Arlington, Virginia: American Psychiatric Association; 2010."},{"issue":"11","key":"316_CR7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905\u201317.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"316_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","volume":"9","author":"D Warden","year":"2007","unstructured":"Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449\u201359.","journal-title":"Curr Psychiatry Rep"},{"issue":"9 Suppl.","key":"316_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2015.07.001","volume":"128","author":"L Culpepper","year":"2015","unstructured":"Culpepper L, Muskin PR, Stahl SM. Major depressive disorder: understanding the significance of residual symptoms and balancing efficacy with tolerability. Am J Med. 2015;128(9 Suppl.):S1-15.","journal-title":"Am J Med"},{"issue":"1","key":"316_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12888-017-1385-0","volume":"17","author":"G Gauthier","year":"2017","unstructured":"Gauthier G, Guerin A, Zhdanava M, Jacobson W, Nomikos G, Merikle E, et al. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis. BMC Psychiatry. 2017;17(1):222.","journal-title":"BMC Psychiatry"},{"key":"316_CR11","unstructured":"Florida Medicaid Drug Therapy Management Program for Behavioral Health at University of South Florida College of Behavioral & Community Sciences. Treatment of adult major depressive disorder 2019-2020. Agency for Health Care Administration State of Florida; 2019. https:\/\/floridabhcenter.org\/wpcontent\/uploads\/2021\/04\/2019-Psychotherapeutic-Medication-Guidelines-for-Adults-with-References_06-04-20.pdf."},{"issue":"2","key":"316_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1192\/apt.bp.107.004820","volume":"15","author":"L Palaniyappan","year":"2018","unstructured":"Palaniyappan L, Insole L, Ferrier N. Combining antidepressants: a review of evidence. Adv Psychiatr Treat. 2018;15(2):90\u20139.","journal-title":"Adv Psychiatr Treat"},{"issue":"10","key":"316_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11920-013-0403-2","volume":"15","author":"ME Thase","year":"2013","unstructured":"Thase ME. Antidepressant combinations: cutting edge psychopharmacology or passing fad? Curr Psychiatry Rep. 2013;15(10):403.","journal-title":"Curr Psychiatry Rep"},{"issue":"9","key":"316_CR14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","volume":"166","author":"JC Nelson","year":"2009","unstructured":"Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980\u201391.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"316_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4088\/JCP.v68n0602","volume":"68","author":"GI Papakostas","year":"2007","unstructured":"Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826\u201331.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"316_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001403","volume":"10","author":"GI Spielmans","year":"2013","unstructured":"Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10(3): e1001403.","journal-title":"PLoS Med"},{"key":"316_CR17","doi-asserted-by":"crossref","unstructured":"Mulder R, Hamilton A, Irwin L, Boyce P, Morris G, Porter RJ, et al. Treating depression with adjunctive antipsychotics. Bipolar Disord. 2018;20 Suppl. 2(S2):17\u201324.","DOI":"10.1111\/bdi.12701"},{"issue":"3","key":"316_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/phar.1204","volume":"33","author":"BM Wright","year":"2013","unstructured":"Wright BM, Eiland EH 3rd, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy. 2013;33(3):344\u201359.","journal-title":"Pharmacotherapy"},{"issue":"2\u20133","key":"316_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0165-0327(98)00138-4","volume":"50","author":"LL Judd","year":"1998","unstructured":"Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2\u20133):97\u2013108.","journal-title":"J Affect Disord"},{"issue":"5","key":"316_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881115581093","volume":"29","author":"A Cleare","year":"2015","unstructured":"Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459\u2013525.","journal-title":"J Psychopharmacol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00316-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-022-00316-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00316-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T04:18:44Z","timestamp":1660969124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-022-00316-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["316"],"URL":"https:\/\/doi.org\/10.1007\/s40801-022-00316-4","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"30 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rakesh Jain has received grant funding from, or served as a consultant, or on advisory boards and speakers\u2019 bureaus for Addrenex, Alkermes, Allergan (now AbbVie), AstraZeneca, Avanir, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Rhodes, Supernus, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva, and Tris Pharmaceuticals. Sara Higa is a former employee of AbbVie and may hold AbbVie stock. Patrick Gillard, Katelyn Keyloun, and Amy Tung are employees of AbbVie and may hold stock. Julie Park is an employee of IBM Watson Health, which received funding from Allergan (prior to its acquisition by AbbVie) to conduct this analysis. Machaon Bonafede was an employee of IBM Watson Health at the time the study was conducted and is currently an employee at Veradigm Health, an Allscripts Company. Andrew J. Cutler has been a consultant for AbbVie, Acadia Pharmaceuticals, Akili Interactive, Alfasigma, Alkermes, Avanir, BioXcel Therapeutics, BlackThorn Therapeutics, Intra-Cellular Therapies, Ironshore, Janssen, Karuna Therapeutics, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Relmada Therapeutics, Sage Therapeutics, Sunovion, Supernus Pharmaceuticals, Takeda, Teva, and Tris Pharma; has received speaker\/promotional honoraria from AbbVie, Acadia Pharmaceuticals, Alfasigma, Alkermes, Avanir, BioXcel Therapeutics, Corium, Intra-Cellular Therapies, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Takeda, Teva, and Tris Pharma; and has received research grants from Aevi Genomics, Akili Interactive, Alkermes, Allergan (now AbbVie), Arbor Pharmaceuticals, Biohaven, Ironshore, KemPharm, Lilly, Lundbeck, Neos Therapeutics, Novartis, Otsuka, Purdue Canada, Sage Therapeutics, Sunovion, Supernus Pharmaceuticals, Takeda, and Tris Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was exempt from ethics committee approval and institutional review because it is a retrospective analysis that used anonymized and de-identified data certified as fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996. Allergan (prior to its acquisition by AbbVie) obtained permission to access and use the IBM<sup>\u00ae<\/sup> MarketScan<sup>\u00ae<\/sup> data used in the analysis through licensing agreements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data that support the findings of this study were used under license from IBM<sup>\u00ae<\/sup> Watson Health<sup>TM<\/sup>. Restrictions apply to the availability of these data, which are not publicly available and cannot be shared.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AC, RJ, MB, JP, PG, KK, AT, and SH were involved with the study design, analysis, and\/or interpretation of the data. MB and JP also performed statistical analyses. All authors contributed to and have approved the final manuscript and are accountable for all aspects of the work, as well as the ability to identify their individual unique contributions and to ensure the integrity of their contributions.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}